Valuation: Imagenetix, Inc.

Market Cap 2.56M 2.27M 2.12M 1.94M 3.65M 246M 3.7M 25.7M 9.95M 125M 9.6M 9.4M 403M P/E 2010
-5.69x
P/E 2011 -1.95x
Enterprise Value 2.49M 2.22M 2.07M 1.89M 3.55M 240M 3.6M 25.07M 9.7M 122M 9.37M 9.16M 393M EV / Sales 2010
0.45x
EV / Sales 2011 0.72x
Free-Float
36.25%
Yield 2010 *
-
Yield 2011 -
6 months+19,900.00%
Current year+19,900.00%
Current year 0
Extreme 0.0002
0
1 year 0
Extreme 0.0002
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 1.0E-6
0.05
Manager TitleAgeSince
Chief Executive Officer - 2015-10-27
Director of Finance/CFO 80 2009-11-22
Chief Executive Officer 73 1998-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%+19,900.00%-.--% 5.71K
+0.50%-2.68%+0.63%-26.92% 231B
-0.10%-5.09%-8.56%-16.77% 73.72B
+1.74%-1.65%-20.67%+13.59% 41.7B
+0.18%-2.88%+34.21%+5.44% 38.33B
+1.07%-4.54%-15.64%-20.38% 32.01B
-0.91%+3.19%+24.75%+82.27% 31.88B
+0.79%-2.24%-14.86%-12.69% 28.39B
-1.14%-5.87%-14.54%-33.23% 26.63B
-0.62%-3.65%+11.80%+15.93% 26.11B
Average +0.25%-3.09%+1,989.71%+0.72% 52.99B
Weighted average by Cap. +0.37%-3.86%-0.47%-10.46%

Financials

2010 2011
Net sales 6.6M 5.86M 5.48M 4.99M 9.4M 635M 9.53M 66.28M 25.66M 323M 24.76M 24.23M 1.04B 7.13M 6.33M 5.92M 5.4M 10.16M 686M 10.3M 71.63M 27.73M 350M 26.77M 26.18M 1.12B
Net income -697K -619K -579K -528K -993K -67.12M -1.01M -7M -2.71M -34.18M -2.62M -2.56M -110M -2.17M -1.93M -1.8M -1.64M -3.09M -209M -3.13M -21.78M -8.43M -106M -8.14M -7.96M -341M
Net Debt -982K -872K -815K -743K -1.4M -94.5M -1.42M -9.86M -3.82M -48.13M -3.69M -3.61M -155M 740K 657K 615K 560K 1.05M 71.25M 1.07M 7.44M 2.88M 36.29M 2.78M 2.72M 117M
Logo Imagenetix, Inc.
Imagenetix, Inc. develops, formulates, markets over-the-counter, natural-based nutritional supplements and skin care products. The Company's products are offered through multiple channels of distribution, including direct marketing companies, also known as network marketing or multi-level marketing companies and chain store retailers. Its primary product is Celadrin, a product formulation, which it sells to the mass market through retailers and on a private label basis to wholesale customers. The Company licenses its intellectual property to third parties. It is focused on two medical need areas, which include human and animal conditions related to inflammation and obesity. It has researched and developed active compositions in the areas of joint health, arthritis and periodontal disease, among others. The Company sells its own branded product, Celadrin, directly to the mass markets through retail sellers. It also offers Celadrin products through wholesale customers.
Employees
5
  1. Stock Market
  2. Stocks
  3. IAGX Stock